CT-based radiomics shows variable accuracy for predicting occult lymph node metastasis in early-stage lung adenocarcinoma
CT scan analysis shows promise for predicting hidden cancer spread in early lung cancer
A meta-analysis of 10 studies including 6,349 patients with early-stage lung adenocarcinoma found CT-based radiomics had pooled sensitivity …
Computer analysis of regular CT scans can spot hidden cancer spread in early lung cancer with about 85% accuracy when tested in the same hos…
Radiomics-ML model predicts invasiveness in subcentimeter subsolid lung adenocarcinoma
AI model shows promise for predicting cancer invasiveness in small lung nodules
A two-center retrospective cohort study of 260 patients with surgically confirmed subcentimeter subsolid lung adenocarcinoma developed and v…
An AI model predicts whether tiny, hazy lung spots are invasive cancer with 79% accuracy, offering a new tool for doctors to spot dangerous …
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
Tumor DNA Levels Help Predict Outcomes in Lung Cancer Treatment
This meta-analysis of 2,107 patients evaluates the role of circulating tumor DNA (ctDNA) as a biomarker for outcomes in advanced NSCLC treat…
Testing for circulating tumor DNA may help doctors predict how well patients with advanced lung cancer respond to immunotherapy treatments.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
Sublobar resection shows mixed survival results for early lung cancer
This umbrella review of meta-analyses indicates sublobar resection carries higher risks for overall and disease-free survival in Stage I non…
An umbrella review found mixed survival results for sublobar resection versus lobectomy in early-stage non-small cell lung cancer.
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
Immunotherapy before lung cancer surgery is safe, study finds
This meta-analysis of patients with resectable non-small cell lung cancer found that neoadjuvant or perioperative immune checkpoint inhibito…
A new analysis of 2,691 patients shows that immunotherapy before lung cancer surgery is feasible, but comes with specific surgical challenge…
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Perspective review on radiation therapy and cardiac toxicity in lung cancer
Radiation planning may help protect heart and immune system in lung cancer patients
This perspective review article synthesizes evidence on thoracic radiation therapy for locally advanced non-small cell lung cancer, focusing…
A perspective review suggests radiation planning techniques could spare the heart and immune system for lung cancer patients.
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Questions about Lung Adenocarcinoma
How does gene expression affect survival in early-stage lung adenocarcinoma?
Gene expression programs involving immune cells, stromal remodeling, and acylation modifications significantly predict survival and recurrence in early-stage lung adenocarcinoma.
Full answer →Can aumolertinib be used again after osimertinib causes lung problems?
Yes, aumolertinib (almonertinib) has been successfully used after osimertinib caused lung problems like interstitial lung disease, based on case reports.
Full answer →